Anti-CD20 chimeric antigen receptor T cell therapy - Beijing Biohealthcare Biotechnology

Drug Profile

Anti-CD20 chimeric antigen receptor T cell therapy - Beijing Biohealthcare Biotechnology

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Beijing Biohealthcare Biotechnology
  • Class CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma

Most Recent Events

  • 31 Aug 2016 Phase-I/II clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (NCT02965157)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top